450 related articles for article (PubMed ID: 29898988)
1. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.
Kugel CH; Douglass SM; Webster MR; Kaur A; Liu Q; Yin X; Weiss SA; Darvishian F; Al-Rohil RN; Ndoye A; Behera R; Alicea GM; Ecker BL; Fane M; Allegrezza MJ; Svoronos N; Kumar V; Wang DY; Somasundaram R; Hu-Lieskovan S; Ozgun A; Herlyn M; Conejo-Garcia JR; Gabrilovich D; Stone EL; Nowicki TS; Sosman J; Rai R; Carlino MS; Long GV; Marais R; Ribas A; Eroglu Z; Davies MA; Schilling B; Schadendorf D; Xu W; Amaravadi RK; Menzies AM; McQuade JL; Johnson DB; Osman I; Weeraratna AT
Clin Cancer Res; 2018 Nov; 24(21):5347-5356. PubMed ID: 29898988
[No Abstract] [Full Text] [Related]
2. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
Chow MT; Ozga AJ; Servis RL; Frederick DT; Lo JA; Fisher DE; Freeman GJ; Boland GM; Luster AD
Immunity; 2019 Jun; 50(6):1498-1512.e5. PubMed ID: 31097342
[TBL] [Abstract][Full Text] [Related]
3. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
4. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
[TBL] [Abstract][Full Text] [Related]
5. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8
Buchan SL; Fallatah M; Thirdborough SM; Taraban VY; Rogel A; Thomas LJ; Penfold CA; He LZ; Curran MA; Keler T; Al-Shamkhani A
Clin Cancer Res; 2018 May; 24(10):2383-2394. PubMed ID: 29514845
[No Abstract] [Full Text] [Related]
6. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.
Yoshida K; Okamoto M; Sasaki J; Kuroda C; Ishida H; Ueda K; Ideta H; Kamanaka T; Sobajima A; Takizawa T; Tanaka M; Aoki K; Uemura T; Kato H; Haniu H; Saito N
BMC Cancer; 2020 Jan; 20(1):25. PubMed ID: 31914969
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
[No Abstract] [Full Text] [Related]
8. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
[TBL] [Abstract][Full Text] [Related]
9. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.
Woods DM; Ramakrishnan R; Laino AS; Berglund A; Walton K; Betts BC; Weber JS
Clin Cancer Res; 2018 Dec; 24(24):6236-6247. PubMed ID: 30131384
[TBL] [Abstract][Full Text] [Related]
10. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.
O'Shaughnessy MJ; Murray KS; La Rosa SP; Budhu S; Merghoub T; Somma A; Monette S; Kim K; Corradi RB; Scherz A; Coleman JA
Clin Cancer Res; 2018 Feb; 24(3):592-599. PubMed ID: 28954788
[No Abstract] [Full Text] [Related]
11. Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer.
de Streel G; Bertrand C; Chalon N; Liénart S; Bricard O; Lecomte S; Devreux J; Gaignage M; De Boeck G; Mariën L; Van De Walle I; van der Woning B; Saunders M; de Haard H; Vermeersch E; Maes W; Deckmyn H; Coulie PG; van Baren N; Lucas S
Nat Commun; 2020 Sep; 11(1):4545. PubMed ID: 32917858
[TBL] [Abstract][Full Text] [Related]
12. CD103
Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
[No Abstract] [Full Text] [Related]
13. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
14. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
15. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
Oh DS; Kim H; Oh JE; Jung HE; Lee YS; Park JH; Lee HK
Oncotarget; 2017 Jul; 8(29):47440-47453. PubMed ID: 28537894
[TBL] [Abstract][Full Text] [Related]
17. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
18. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
20. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]